Compare BioNTech SE - ADR (BNTX) vs Dropbox Inc (DBX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Dropbox Inc — how do they compare? BioNTech SE - ADR trades at $92.64 (market cap $23.31B), while Dropbox Inc trades at $33.51 (market cap $7.52B). The key difference: BioNTech SE - ADR is far larger — about 3.1× Dropbox Inc's market cap, and Dropbox Inc is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| BNTX | DBX | |
|---|---|---|
Market Cap | $23.31B | $7.52B |
Sector | Health | Technology |
52-Week High | $119.34 | $35.00 |
52-Week Low | $83.89 | $22.06 |
Enterprise Value | $6.60B | $10.38B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $93.67, up 2.72% today, with a bullish technical signal and strong analyst support. The stock faces fundamental challenges, including declining COVID-19 vaccine revenue and negative profitability, but holds a robust cash position of $16.78 billion. Recent news highlights leadership changes and pipeline advancements in oncology, with a consensus price target of $121.00 implying significant upside potential.
Outlook: Long-term growth hinges on oncology pipeline success, but near-term risks from vaccine demand volatility and net losses persist. Investment opportunity lies in discounted valuation relative to cash and pipeline assets, though execution risks and competitive pressures require careful monitoring.
Dropbox (DBX) trades at $34.81, up 0.78% today, with a bullish technical signal and consistent earnings beats. The company reported Q2 2026 EPS of $0.75, exceeding estimates, and raised its full-year outlook. Revenue remains stable at $2.5B, with strong gross margins of 79.72%. However, negative shareholder equity and high debt levels pose financial risks.
The outlook is mixed: strong profitability and AI-driven growth support upside, but elevated leverage and competitive pressures warrant caution. Analyst sentiment is divided, with 37.5% recommending Buy. Key risks include execution challenges and market volatility. The stock's trajectory hinges on sustaining core business momentum amid macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Dropbox Inc
Dropbox is a leading provider of cloud-storage and content collaboration tools with an emphasis on individuals and SMB. The company was founded in 2007 and was a pioneer in cloud storage and cross-platform file syncing. Utilizing inorganic and organic means, the firm has been working on diversifying its product mix and pivoting away from the cloud-storage space.
Read more on DBX →
